Posted by Michael Wonder on 27 Jul 2023
FDA grants breakthrough therapy designation to NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy
27 July 2023 - NS Pharma announced today the US FDA has granted breakthrough therapy designation to NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.
The breakthrough therapy designation for NS-089/NCNP-02 is based on results from a first in human, investigator initiated clinical trial conducted in Japan.
